Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

BP has appointed its fourth CEO in 6 years – but will she be radically different?

December 18, 2025

Meg O’Neill, chief executive officer of Woodside Energy Group Ltd., attends the company’s annual general meeting in Perth, Australia on Thursday, May 8, 2025. Photographer: Matt Jelonek/Bloomberg via Getty Images Bloomberg | Bloomberg | Getty Images BP is changing its CEO again, but not its direction. The appointment of Woodside Energy boss Meg O’Neill as […]

World

Bank of Japan is poised to raise rates to a 30-year high despite economic weakness

December 18, 2025

Kazuo Ueda, governor of the Bank of Japan (BOJ), gestures to speak during a budget committee session at the lower house of parliament in Tokyo, Japan, on Tuesday, Dec. 9, 2025. Ueda said the recent pace of increases in Japans long-term bond yields is “somewhat fast,” while adding that long-term yields should be determined by […]

World

BP names new CEO — its fourth in 6 years

December 18, 2025

British oil giant BP has appointed Woodside Energy boss Meg O’Neill as its next CEO, replacing Murray Auchincloss after less than two years in the role. Auchincloss will step down today, with Carol Howle, BP’s executive vice president for supply, trading and shipping set to serve as interim CEO until O’Neill takes over the role […]